Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam L Halberstadt

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
Psychopharmacology|August 19, 2016
Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challengesZackary A Cope, Adam L Halberstadt, Jordy van Enkhuizen, et al.
Plos One|June 18, 2016
Pharmacological Investigations of the Dissociative 'Legal Highs' Diphenidine, Methoxphenidine and AnaloguesJason Wallach, Heather Kang, Tristan Colestock, et al.
ACS Pharmacology & Translational Science|February 15, 2024
Serotonin-2 Receptor Agonists Produce Anti-inflammatory Effects through Functionally Selective Mechanisms That Involve the Suppression of Disease-Induced Arginase 1 ExpressionThomas W Flanagan, Timothy P Foster, Thomas E Galbato, et al.
Drug Testing and Analysis|March 18, 2020
Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Journal of Medicinal Chemistry|September 25, 2025
Discovery of Highly Selective 5-HT<sub>2A</sub> Agonists Using Structure-Guided DesignTyler G Fenske, John L McKee, Natalie G Cavalco, et al.
European Journal of Pharmacology|June 2, 2019
Pharmacological characterizations of the 'legal high' fluorolintane and isomersJason Wallach, Tristan Colestock, Julià Agramunt, et al.
Drug Testing and Analysis|June 7, 2016
Return of the lysergamides. Part II: Analytical and behavioural characterization of N<sup>6</sup> -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Drug Testing and Analysis|June 7, 2017
Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)Simon D Brandt, Pierce V Kavanagh, Brendan Twamley, et al.
Biochemical Pharmacology|April 17, 2020
The selective 5-HT<sub>2A</sub> receptor agonist 25CN-NBOH: Structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [<sup>3</sup>H]25CN-NBOHAnders A Jensen, Adam L Halberstadt, Emil Märcher-Rørsted, et al.
Schizophrenia Bulletin|October 6, 2025
Visual Hallucinations in Serotonergic Psychedelics and Lewy Body DiseasesNathan H Heller, Frederick S Barrett, Tobias Buchborn, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Psychopharmacology|August 19, 2016
Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challengesZackary A Cope, Adam L Halberstadt, Jordy van Enkhuizen, et al.
Plos One|June 18, 2016
Pharmacological Investigations of the Dissociative 'Legal Highs' Diphenidine, Methoxphenidine and AnaloguesJason Wallach, Heather Kang, Tristan Colestock, et al.
ACS Pharmacology & Translational Science|February 15, 2024
Serotonin-2 Receptor Agonists Produce Anti-inflammatory Effects through Functionally Selective Mechanisms That Involve the Suppression of Disease-Induced Arginase 1 ExpressionThomas W Flanagan, Timothy P Foster, Thomas E Galbato, et al.
Drug Testing and Analysis|March 18, 2020
Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Journal of Medicinal Chemistry|September 25, 2025
Discovery of Highly Selective 5-HT<sub>2A</sub> Agonists Using Structure-Guided DesignTyler G Fenske, John L McKee, Natalie G Cavalco, et al.
European Journal of Pharmacology|June 2, 2019
Pharmacological characterizations of the 'legal high' fluorolintane and isomersJason Wallach, Tristan Colestock, Julià Agramunt, et al.
Drug Testing and Analysis|June 7, 2016
Return of the lysergamides. Part II: Analytical and behavioural characterization of N<sup>6</sup> -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Drug Testing and Analysis|June 7, 2017
Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)Simon D Brandt, Pierce V Kavanagh, Brendan Twamley, et al.
Biochemical Pharmacology|April 17, 2020
The selective 5-HT<sub>2A</sub> receptor agonist 25CN-NBOH: Structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [<sup>3</sup>H]25CN-NBOHAnders A Jensen, Adam L Halberstadt, Emil Märcher-Rørsted, et al.
Schizophrenia Bulletin|October 6, 2025
Visual Hallucinations in Serotonergic Psychedelics and Lewy Body DiseasesNathan H Heller, Frederick S Barrett, Tobias Buchborn, et al.
Pageof 9